Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

Similar articles for PubMed (Select 19932670)

1.

The expanding vaccine development pipeline, 1995-2008.

Davis MM, Butchart AT, Coleman MS, Singer DC, Wheeler JR, Pok A, Freed GL.

Vaccine. 2010 Feb 3;28(5):1353-6. doi: 10.1016/j.vaccine.2009.11.007. Epub 2009 Nov 21. Review.

PMID:
19932670
2.
3.

Cancer vaccine THERATOPE- Biomira.

Adis International Ltd.

Drugs R D. 2003;4(4):236-40.

PMID:
12848588
4.

Progress and challenges towards the development of malaria vaccines.

Tetteh KK, Polley SD.

BioDrugs. 2007;21(6):357-73. Review.

PMID:
18020620
6.

Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline.

Davis MM, Butchart AT, Wheeler JR, Coleman MS, Singer DC, Freed GL.

Vaccine. 2011 Nov 28;29(51):9414-6. doi: 10.1016/j.vaccine.2011.09.128. Epub 2011 Oct 12.

PMID:
22001883
7.

Risk in vaccine research and development quantified.

Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD.

PLoS One. 2013;8(3):e57755. doi: 10.1371/journal.pone.0057755. Epub 2013 Mar 20.

8.

Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.

[No authors listed]

BioDrugs. 2003;17(1):69-72.

PMID:
12534322
9.

Women and vaccinations: From smallpox to the future, a tribute to a partnership benefiting humanity for over 200 years.

Datta SK, Bhatla N, Burgess MA, Lehtinen M, Bock HL.

Hum Vaccin. 2009 Jul;5(7):450-4. Epub 2009 Jul 20. Review.

10.
11.

Alternative strategies in drug development: clinical pharmacological aspects.

Kuhlmann J.

Int J Clin Pharmacol Ther. 1999 Dec;37(12):575-83. Review.

PMID:
10599949
12.

[Tuberculosis vaccines].

Wiker HG, Bjune G.

Tidsskr Nor Laegeforen. 2006 Oct 19;126(20):2678-81. Review. Norwegian.

13.
14.

Antituberculous vaccine development: a perspective for the endemic world.

Verma I, Grover A.

Expert Rev Vaccines. 2009 Nov;8(11):1547-53. doi: 10.1586/erv.09.111. Review.

PMID:
19863247
15.
16.

South African HIV-1 vaccine candidates - the journey from the bench to clinical trials.

Williamson AL, Rybiki E, Shephard E, Gray G, Bekker LG, Downing K, Williamson C.

S Afr Med J. 2012 Mar 2;102(6):452-5.

PMID:
22668934
17.

Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.

Ferrantelli F, Buttò S, Cafaro A, Wahren B, Ensoli B.

Springer Semin Immunopathol. 2006 Nov;28(3):289-301. Epub 2006 Sep 16. Review.

PMID:
16983452
18.

[France, an attractive country for international clinical research: 2008 survey assessed by Leem (French association of pharmaceutical companies)].

Lassale C, Sibenaler C, Béhier JM, Plétan Y, Courcier S; groupe de travail attractivite de la France du Leem.

Therapie. 2008 Sep-Oct;63(5):345-57. doi: 10.2515/therapie:2008061. Epub 2009 Jan 21. French.

PMID:
19154705
19.

Public vaccine manufacturing capacity in the Latin American and Caribbean region: current status and perspectives.

Cortes Mde L, Cardoso D, Fitzgerald J, DiFabio JL.

Biologicals. 2012 Jan;40(1):3-14. doi: 10.1016/j.biologicals.2011.09.013. Epub 2011 Oct 26. Review.

PMID:
22033155
20.

Update on research and development pipeline: tuberculosis vaccines.

Beresford B, Sadoff JC.

Clin Infect Dis. 2010 May 15;50 Suppl 3:S178-83. doi: 10.1086/651489. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk